High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cells

Register data suggest that patients with Hodgkin's disease (HD) given high-dose therapy (HDT) with peripheral blood progenitor cells (PBPC) have a less favourable prognosis as compared to those given bone marrow as stem cell support. Since this can be due to infusion of tumour cells contaminati...

Descripción completa

Detalles Bibliográficos
Autores principales: Blystad, AK, Holte, H, Kvaløy, S, Smeland, E, Delabie, J, Kvalheim, G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2001
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091626/
https://www.ncbi.nlm.nih.gov/pubmed/11781645
http://dx.doi.org/10.1038/sj.bmt.1703244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091626/
https://www.ncbi.nlm.nih.gov/pubmed/11781645
http://dx.doi.org/10.1038/sj.bmt.1703244

Ejemplares similares